SCHEMBL24263227

SCHEMBL24263227

O=C(NC1CCc2n[nH]c(=O)cc2C1)c1ccc(C2CCCCC2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC8 Q9BY41 2/20 0.42
HDAC6 Q9UBN7 2/20 0.42
HDAC1 Q13547 1/20 0.42
DEGS1 O15121 2/20 0.40
ITK Q08881 1/20 0.40
HDAC3 O15379 1/20 0.40
HDAC11 Q96DB2 1/20 0.40
MAOA P21397 1/20 0.40
MAOB P27338 1/20 0.40
NPC1 O15118 6/20 0.39
RAB9A P51151 5/20 0.39
NAMPT P43490 2/20 0.39
HAO1 Q9UJM8 1/20 0.39
HPGD P15428 3/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
TAOK1 Q7L7X3 1/20 0.38
TAOK3 Q9H2K8 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2C19 P33261 1/20 0.38
GAA P10253 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24263134 0.85 SMYD3 (0.39) HDAC8NPC1RAB9ANAMPTSMN1; SMN2
SCHEMBL24263131 0.85 HDAC8 (0.45) HDAC8NAMPTGAACCNA2CDK2
SCHEMBL24263128 0.85 RAB9A (0.47) NPC1RAB9ANAMPTHPGDSMN1; SMN2
SCHEMBL24263129 0.85 HDAC8 (0.48) HDAC8NPC1RAB9ACCNA2CDK2
SCHEMBL24263090 0.85 NPC1 (0.47) HDAC8HDAC6NPC1RAB9ANAMPT
SCHEMBL24263127 0.85 MTNR1A (0.46) HDAC8NPC1RAB9ASMN1; SMN2GAA
SCHEMBL24263084 0.83 KMT2A (0.42) HDAC1NPC1RAB9ANAMPTHPGD
SCHEMBL24263197 0.82 TAOK1 (0.48) TAOK1GAAALDH1A1
SCHEMBL24263089 0.82 KDM5A (0.40) HDAC8NPC1RAB9ASMN1; SMN2TAOK1
SCHEMBL24263243 0.79 GAA (0.43) GAATSHRALDH1A1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022040508-A1 COMPOUNDS AND METHODS FOR TREATING AUTOIMMUNE DISORDERS BY TARGETING HLA-DQ2 IMMUNOMOLECULAR THERAPEUTICS, INC. (US) 2022-02-24 WO disclosed